Omics Meets Biology: Application to the Design and Preclinical Assessment of Antivenoms
AbstractSnakebite envenoming represents a neglected tropical disease that has a heavy public health impact worldwide, mostly affecting poor people involved in agricultural activities in Africa, Asia, Latin America and Oceania. A key issue that complicates the treatment of snakebite envenomings is the poor availability of the only validated treatment for this disease, antivenoms. Antivenoms can be an efficacious treatment for snakebite envenoming, provided they are safe, effective, affordable, accessible and administered appropriately. The shortage of antivenoms in various regions, particularly in Sub-Saharan Africa and some parts of Asia, can be significantly alleviated by optimizing the use of current antivenoms and by the generation of novel polyspecific antivenoms having a wide spectrum of efficacy. Complementing preclinical testing of antivenom efficacy using in vivo and in vitro functional neutralization assays, developments in venomics and antivenomics are likely to revolutionize the design and preclinical assessment of antivenoms by being able to test new antivenom preparations and to predict their paraspecific neutralization to the level of species-specific toxins. View Full-Text
Share & Cite This Article
Calvete, J.J.; Sanz, L.; Pla, D.; Lomonte, B.; Gutiérrez, J.M. Omics Meets Biology: Application to the Design and Preclinical Assessment of Antivenoms. Toxins 2014, 6, 3388-3405.
Calvete JJ, Sanz L, Pla D, Lomonte B, Gutiérrez JM. Omics Meets Biology: Application to the Design and Preclinical Assessment of Antivenoms. Toxins. 2014; 6(12):3388-3405.Chicago/Turabian Style
Calvete, Juan J.; Sanz, Libia; Pla, Davinia; Lomonte, Bruno; Gutiérrez, José M. 2014. "Omics Meets Biology: Application to the Design and Preclinical Assessment of Antivenoms." Toxins 6, no. 12: 3388-3405.